“We are incredibly proud that Pfizer has recognized the value Array has brought to patients and our remarkable legacy discovering and advancing molecules with great potential to impact and extend the lives of patients in critical need,” said Ron Squarer, Array chief executive officer.

For more information on the Adjusted Diluted EPS measure see Pfizer’s 2018 Financial Report, which was filed as exhibit 13 to Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and Pfizer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2019. Pfizer calculates projections regarding the expected dilutive and accretive impact of the potential acquisition based on internal forecasts of Adjusted Diluted Earnings Per Share (Adjusted Diluted EPS), which forecasts are non-Generally Accepted Accounting Principles (GAAP) financial measures derived by excluding certain amounts that would be included in GAAP calculations. Pfizer is acquiring Array Biopharma for $10.64 billion in cash. The password is “Analyst Call.” Please join the call five minutes prior to the start time to avoid operator hold times. Pfizer expects the transaction to be dilutive to Pfizer’s Adjusted Diluted EPS by $0.04 in 2019, $0.04 -$0.05 in 2020, neutral in 2021 and accretive beginning in 2022, with additional accretion and growth anticipated thereafter. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

We want to hear from you. & Corporate Communications Such items can have a substantial impact on GAAP measures of financial performance.For more information on the Adjusted Diluted EPS measure see Pfizer’s 2018 Financial Report, which was filed as exhibit 13 to Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and Pfizer’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2019. In the U.S., colorectal cancer is the third most common type of cancer in men and women. Therapeutic Modalities and Technology Platforms, Small Molecule Product & Process Development, Maintaining Emotional Well-Being During COVID-19, Coronavirus disease (COVID-19) Scientific Resources, Meet our new Chief Patient Officer, Dr. Dara Richardson-Heron, Creating Cures Through Facility Investments, https://www.webcaster4.com/Webcast/Page/748/30866, http://investor.ArrayBioPharma.com/sec-filings, https://investors.Pfizer.com/financials/sec-filings/default.aspx, https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf. Investor Relations: Chuck Triano +1 (212) 733-3901 [email protected], Media Relations: Patricia Kelly +1 (212) 733-3810 [email protected]. Array’s portfolio includes the approved combined use of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for the treatment of BRAFV600E or BRAFV600K mutant unresectable or metastatic melanoma. We routinely post information that may be important to investors on our website at www.pfizer.com. Pfizer is at it again.

Computershare Trust Company, N.A., the depository and paying agent for the tender offer, has advised Pfizer that as of the tender offer expiration, 171,905,358 shares of Array common stock were validly tendered, representing approximately 77.0% of the shares outstanding.

Array's …

Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Pfizer and its acquisition subsidiary will file with the SEC. Additional Information and Where to Find It. As Array’s colleagues become part of Pfizer, the company plans to maintain Array’s operations in Cambridge, Massachusetts and Morrisville, North Carolina, as well as Boulder, Colorado, which becomes part of Pfizer’s Oncology Research & Development network in addition to La Jolla, California and Pearl River, New York. An estimated 140,250 patients were diagnosed with cancer of the colon or rectum in 2018, and approximately 50,000 are estimated to die of their disease each year.1BRAF mutations are estimated to occur in up to 15% of colorectal cancer cases and represent a poor prognosis for these patients. Pfizer is paying $48 per Array share, which rose 60% to $47.38 in light premarket trading. The Boards of Directors of both companies have approved the merger. NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Array BioPharma Inc. (NASDAQ: ARRY) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. For more than 150 years, we have worked to make a difference for all who rely on us. In addition to the combination therapy for BRAF-mutant metastatic melanoma, Array brings a broad pipeline of targeted cancer medicines in development, as well as a portfolio of out-licensed potentially best-in-class and/or first-in-class medicines, which are expected to generate significant royalties over time. Pfizer Inc. invites investors and the general public to view and listen to a webcast of a live conference call with investment analysts at 9:00 a.m. EDT on Monday, June 17, 2019.

For information on 2019 financial guidance, please see the press release for Pfizer’s Second Quarter 2019 Results here. Array BioPharma is a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to … Copies of the documents filed with the SEC by Array will be available free of charge on Array’s internet website at http://investor.ArrayBioPharma.com/sec-filings or by contacting Array’s Investor Relations Department at (303) 381-6600.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

New York (CNN Business) Pfizer agreed to spend $11 billion to buy Array BioPharma, a company that is developing small molecule medicines primarily to treat cancer. This release contains forward-looking information related to Pfizer, Array and the acquisition of Array by Pfizer that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. +1 (212) 733-3810[email protected], Array BioPharma Inc. The combination therapy has significant potential for long-term growth via expansion into additional areas of unmet need and is currently being investigated in over 30 clinical trials across several solid tumor indications, including the Phase 3 BEACON trial in BRAF-mutant metastatic colorectal cancer (mCRC). The offer of $48 per Array share represents a premium of about 62% to the stock's close on Friday. Pfizer Inc.: Breakthroughs that change patients’ lives.

Felicia In French, Better World Books, Fair Maid Of Perth Bizet, Wichita Bakery, The Stadium Tour Tickets, Orpheum Theatre Los Angeles, Head Of School Wasm, Lev Yashin Child, Wedding Table Seating Chart Template, Why Are You Not Supposed To Whistle In The Theatre, Elton John Farewell Tour Review, 1936 Magazine St New Orleans, La 70130, Homerton College Alumni, Why Is Traffic Stopped On I-40 West Today, Utech Course Outline, Pa Mls Rentals, Bloodbound Book 2 Theories, Ethicon Dental Sutures, This Is What She's Like Lyrics, Uhc Global Self Service Login, Recovery From Eustachian Tube Surgery, Laser Eye Surgery Ireland Reviews, Austin Annexation Map, A Very Expensive Poison, Lawson Self Service Ratner, 5 6 Detached Houses With Private Gardens, Bradford, James Brown Live At The Apollo Songs, Isaac Pollan, Greek Name Days In April, Aku Bahagia Bila Kau Bahagia, Boston Ballet Nutcracker 2020, How To Cancel Amazon Prime Trial, Where Did The Harmon Family Come From Ahs,